Merck jumps as investors focus on reorganization plan and improving Keytruda patent-cliff outlook

Merck & Co. (MRK) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed optimism around Merck’s post-Keytruda strategy after the company outlined a significant commercial reorganization and Wall Street highlighted ways the Keytruda patent cliff could be less abrupt than feared. Recent analyst upgrades/price-target increases and discussion of potential additional Keytruda patent coverage into 2029 may also be helping sentiment.

Details:

Merck disclosed a revamp of its human-health operations, separating an oncology-focused unit from a non-oncology business to sharpen execution as Keytruda approaches loss of exclusivity later this decade.

Management has pointed to additional patents that could potentially extend Keytruda intellectual-property protection beyond the widely cited 2028 timing, which some analysts view as a potential cushion for the revenue transition.

In the wake of the restructuring and updated patent-cliff framing, several firms have leaned more constructive on the stock via upgrades and/or higher price targets, supporting near-term momentum.

This could also be partially driven by broader “defensive” rotation into large-cap pharmaceuticals if markets are risk-off, though that is more speculative.

Sources:

The Wall Street Journal, Financial Times, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRK Insider Trading Activity

$MRK insiders have traded $MRK stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:

JENNIFER ZACHARY (EVP, General Counsel) has made 0 purchases and 3 sales selling 121,573 shares for an estimated $14,485,690.
ROBERT M DAVIS (Chairman, CEO & President) has made 0 purchases and 2 sales selling 47,434 shares for an estimated $5,599,327.
CAROLINE LITCHFIELD (EVP & CFO) sold 41,997 shares for an estimated $5,023,311
CHIRFI GUINDO (Chief Marketing Officer) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $4,836,339.
RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) sold 37,685 shares for an estimated $4,557,024
JOHANNES JACOBUS OOSTHUIZEN (President, U.S. Market) sold 15,000 shares for an estimated $1,827,991
DEAN Y LI (Executive VP & President, MRL) sold 15,087 shares for an estimated $1,791,824
DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) has made 0 purchases and 2 sales selling 13,614 shares for an estimated $1,329,564.
DALTON E. III SMART (SVP Fin. - Global Controller) has made 0 purchases and 2 sales selling 6,400 shares for an estimated $765,920.
CRISTAL N DOWNING (Chief Comm. & Public Afrs Ofcr) sold 7,085 shares for an estimated $616,395

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MRK Hedge Fund Activity

We have seen 1,683 institutional investors add shares of $MRK stock to their portfolio, and 1,662 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 59,566,057 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $6,269,923,159
WELLINGTON MANAGEMENT GROUP LLP added 11,156,354 shares (+14.8%) to their portfolio in Q4 2025, for an estimated $1,174,317,822
CARDANO RISK MANAGEMENT B.V. added 9,619,320 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,012,529,623
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 8,764,580 shares (-46.8%) from their portfolio in Q4 2025, for an estimated $922,559,690
FMR LLC added 7,409,816 shares (+22.2%) to their portfolio in Q4 2025, for an estimated $779,957,232
MILLENNIUM MANAGEMENT LLC added 6,036,983 shares (+790.8%) to their portfolio in Q4 2025, for an estimated $635,452,830
JPMORGAN CHASE & CO removed 6,001,669 shares (-17.0%) from their portfolio in Q4 2025, for an estimated $631,735,678

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MRK Government Contracts

We have seen $6,263,344 of award payments to $MRK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ERVEBO PROCUREMENT: $2,843,515
VACCINE STORAGE AND ROTATION, 2021-2026: $1,267,628
WA COLUMBIA RIV FPO PIT TAGS URGENT: $499,552
EMERGENCY WINREVAIR: $347,167
OR-KLAMATH FALLS FWO-BIOMARK PURCH REQUE: $297,003

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$MRK Congressional Stock Trading

Members of Congress have traded $MRK stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 12/19, 11/18 and 0 sales.
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$MRK Analyst Ratings

Wall Street analysts have issued reports on $MRK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 12/15/2025
Wells Fargo issued a "Overweight" rating on 11/24/2025

To track analyst ratings and price targets for $MRK, check out Quiver Quantitative's $MRK forecast page.

$MRK Price Targets

Multiple analysts have issued price targets for $MRK recently. We have seen 16 analysts offer price targets for $MRK in the last 6 months, with a median target of $120.0.

Here are some recent targets:

An analyst from RBC Capital set a target price of $142.0 on 02/25/2026
Emily Field from Barclays set a target price of $140.0 on 02/20/2026
Vamil Divan from Guggenheim set a target price of $140.0 on 02/06/2026
Carter Gould from Cantor Fitzgerald set a target price of $120.0 on 02/04/2026
Mohit Bansal from Wells Fargo set a target price of $135.0 on 02/04/2026
Geoff Meacham from Citigroup set a target price of $120.0 on 02/04/2026
Steve Scala from TD Cowen set a target price of $120.0 on 01/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.